Skip to content
Catalyst

methylcob(III)alaminWhat was measured

Measured, with no finding

1,487 endpoints

Show what was measuredHide what was measured
  • color vision

    increases, p = 0.05

    The methylprednisolone pulse treatment group showed faster recovery of visual function, particularly the visual acuity at 1 week (P<.05), Humphrey field analyzer mean deviation at 3 weeks (P<.05), and color vision at 1 week (P<.05)

    PMID 10340796 · one of two readings recorded this

  • contrast sensitivity recovery

    increases, p = 0.01

    Recovery of contrast sensitivity at several different spatial frequencies was significant in the pulse treatment group at 1 (P<.01), 2 (P<.05), and 4 weeks (P<.05) after the start of treatment

    PMID 10340796 · one of two readings recorded this

  • contrast sensitivity recovery

    increases, p = 0.05

    Recovery of contrast sensitivity at several different spatial frequencies was significant in the pulse treatment group at 1 (P<.01), 2 (P<.05), and 4 weeks (P<.05) after the start of treatment

    PMID 10340796 · one of two readings recorded this

  • contrast sensitivity recovery

    increases, p = 0.05

    Recovery of contrast sensitivity at several different spatial frequencies was significant in the pulse treatment group at 1 (P<.01), 2 (P<.05), and 4 weeks (P<.05) after the start of treatment

    PMID 10340796 · one of two readings recorded this

  • Humphrey field analyzer mean deviation

    increases, p = 0.05

    The methylprednisolone pulse treatment group showed faster recovery of visual function, particularly the visual acuity at 1 week (P<.05), Humphrey field analyzer mean deviation at 3 weeks (P<.05), and color vision at 1 week (P<.05)

    PMID 10340796 · one of two readings recorded this

  • side effects frequency

    increases, p = 0.05

    Side effects appeared more frequently in the pulse treatment group than in the control (P<.05)

    PMID 10340796 · one of two readings recorded this

  • visual acuity

    increases, p = 0.05

    The methylprednisolone pulse treatment group showed faster recovery of visual function, particularly the visual acuity at 1 week (P<.05), Humphrey field analyzer mean deviation at 3 weeks (P<.05), and color vision at 1 week (P<.05)

    PMID 10340796 · one of two readings recorded this

  • visual function test results

    no effect

    Visual function test results at 12 weeks and 1 year were essentially the same in the two treatment groups

    PMID 10340796 · one of two readings recorded this

  • visual function test results

    no effect

    Visual function test results at 12 weeks and 1 year were essentially the same in the two treatment groups

    PMID 10340796 · one of two readings recorded this

  • neuropathic pain grading; ulnar motor and median sensory nerve conduction velocities in haemodialysis patients

    increases, ulnar motor and median sensory nerve conduction velocities showed significant improvement after 6 months; single-arm, no control, n = 9

    Not recorded as a finding: this platform holds no node for the endpoint

    After 6 months of treatment, the patients' pain or paresthesia had lessened, and the ulnar motor and median sensory nerve conduction velocities showed significant improvement.

    PMID 10411351 · one of two readings recorded this

  • pain or paresthesia

    decreases

    After 6 months of treatment, the patients' pain or paresthesia had lessened

    PMID 10411351 · one of two readings recorded this

  • serum vitamin B12 concentration

    increases

    Serum concentrations of vitamin B12 were ultra-high during treatment due to the lack of urinary excretion

    PMID 10411351 · one of two readings recorded this

  • ulnar motor and median sensory nerve conduction velocities

    increases

    the ulnar motor and median sensory nerve conduction velocities showed significant improvement

    PMID 10411351 · one of two readings recorded this

  • neurogenic claudication distance

    increases, n = 152

    there was no significant difference between the 2 groups in terms of pain improvement and neurological signs, except neurogenic claudication distance which was better in the M-group

    PMID 10998833 · one of two readings recorded this

  • neurological signs

    no effect, n = 152

    there was no significant difference between the 2 groups in terms of pain improvement and neurological signs, except neurogenic claudication distance which was better in the M-group

    PMID 10998833 · one of two readings recorded this

  • pain improvement, neurological signs and neurogenic claudication distance in degenerative lumbar spinal stenosis (instrument not stated)

    no effect

    Not recorded as a finding: this platform holds no node for the endpoint

    Most of the patients in both groups showed improvement but there was no significant difference between the 2 groups in terms of pain improvement and neurological signs, except neurogenic claudication distance which was better in the M-group.

    PMID 10998833 · one of two readings recorded this

  • pain improvement

    no effect, n = 152

    there was no significant difference between the 2 groups in terms of pain improvement and neurological signs, except neurogenic claudication distance which was better in the M-group

    PMID 10998833 · one of two readings recorded this

  • coldness response rate

    increases

    Hypoesthesia, hotness, coldness, oral dryness and dysuria showed better response in the mecobalamin group than in the controls (55% vs 25%, 52% vs 18%, 59% vs 30%, 53% vs 19%, 63% vs 20% respectively)

    PMID 11798619 · one of two readings recorded this

  • dysuria response rate

    increases

    Hypoesthesia, hotness, coldness, oral dryness and dysuria showed better response in the mecobalamin group than in the controls (55% vs 25%, 52% vs 18%, 59% vs 30%, 53% vs 19%, 63% vs 20% respectively)

    PMID 11798619 · one of two readings recorded this

  • hotness response rate

    increases

    Hypoesthesia, hotness, coldness, oral dryness and dysuria showed better response in the mecobalamin group than in the controls (55% vs 25%, 52% vs 18%, 59% vs 30%, 53% vs 19%, 63% vs 20% respectively)

    PMID 11798619 · one of two readings recorded this

  • hypoesthesia response rate

    increases

    Hypoesthesia, hotness, coldness, oral dryness and dysuria showed better response in the mecobalamin group than in the controls (55% vs 25%, 52% vs 18%, 59% vs 30%, 53% vs 19%, 63% vs 20% respectively)

    PMID 11798619 · one of two readings recorded this

  • improvement of spontaneous pain and numbness of limbs and other neuropathic symptoms, nerve reflection and conduction velocity, mecobalamin versus vitamin B12 (active control)

    increases

    Not recorded as a finding: this platform holds no node for the endpoint

    Twelve weeks after the treatment, spontaneous pain and numbness of limbs were improved by 73% and 75% in the mecobalamin group, which were much higher than those in the controls (36% and 45% respectively).

    PMID 11798619 · one of two readings recorded this

  • nerve reflection and conduction velocity

    increases

    Mecobalamin also benefited nerve reflection and conduction velocity to a certain extent

    PMID 11798619 · one of two readings recorded this

  • numbness of limbs improvement rate

    increases

    spontaneous pain and numbness of limbs were improved by 73% and 75% in the mecobalamin group, which were much higher than those in the controls (36% and 45% respectively)

    PMID 11798619 · one of two readings recorded this

  • oral dryness response rate

    increases

    Hypoesthesia, hotness, coldness, oral dryness and dysuria showed better response in the mecobalamin group than in the controls (55% vs 25%, 52% vs 18%, 59% vs 30%, 53% vs 19%, 63% vs 20% respectively)

    PMID 11798619 · one of two readings recorded this

  • spontaneous pain improvement rate

    increases

    spontaneous pain and numbness of limbs were improved by 73% and 75% in the mecobalamin group, which were much higher than those in the controls (36% and 45% respectively)

    PMID 11798619 · one of two readings recorded this

  • fasting total homocysteine before vs after therapy

    decreases, p = 0.003

    Mean tHcy levels showed a significant decrease in group A from 22.5 +/- 15.6 to 10.2 +/- 3.1 micromol/l (p = 0.003)

    PMID 12021520 · one of two readings recorded this

  • fasting total homocysteine before vs after therapy

    decreases, p = 0.012

    and in group B from 19.9 +/- 4.0 to 11.2 +/- 1.9 micromol/l (p = 0.012)

    PMID 12021520 · one of two readings recorded this

  • fasting total homocysteine before vs after therapy

    no effect

    no significant changes were observed in groups C (25.9 +/- 9.3 vs. 27.3 +/- 9.7 micromol/l, p = n.s.)

    PMID 12021520 · one of two readings recorded this

  • fasting total homocysteine before vs after therapy

    no effect

    and D (26.6 +/- 14.3 vs. 24.3 +/- 11.8 micromol/l, p = n.s.)

    PMID 12021520 · one of two readings recorded this

  • final fasting total homocysteine

    no effect

    similar to group B (11.2 +/- 1.9 micromol/l, p = n.s.)

    PMID 12021520 · one of two readings recorded this

  • final fasting total homocysteine

    decreases, p = 0.001

    Final tHcy levels were significantly lower in group A (10.2 +/- 3.1 micromol/l) compared to groups C (27.3 +/- 9.7 micromol/l, p < 0.001)

    PMID 12021520 · one of two readings recorded this

  • final fasting total homocysteine

    decreases, p = 0.001

    group A (10.2 +/- 3.1 micromol/l) compared to groups C (27.3 +/- 9.7 micromol/l, p < 0.001) and group D (24.3 +/- 11.8 micromol/l, p < 0.001)

    PMID 12021520 · one of two readings recorded this

  • motor and sensory nerve conduction

    no effect

    Motor and sensory nerve conduction studies showed no statistical improvement after 4 months

    PMID 1324807 · one of two readings recorded this

  • somatic and autonomic symptoms and signs of diabetic neuropathy

    decreases

    In a double-blind study, the active group showed statistical improvement in the somatic and autonomic symptoms with regression of signs of diabetic neuropathy

    PMID 1324807 · one of two readings recorded this

  • somatic and autonomic symptoms of diabetic neuropathy; motor and sensory nerve conduction studies

    no effect, nerve conduction showed no statistical improvement after 4 months

    Not recorded as a finding: this platform holds no node for the endpoint

    Motor and sensory nerve conduction studies showed no statistical improvement after 4 months.

    PMID 1324807 · one of two readings recorded this

  • serum tHcy, sublingual versus oral

    no effect

    There was no statistically significant difference in serum tHcy concentrations between SL and PO groups either before or after treatment

    PMID 17109579 · one of two readings recorded this

  • total serum homocysteine (tHcy)

    decreases

    A statistically significant reduction in tHcy values was observed in both groups upon completion of the 6-week protocol

    PMID 17109579 · one of two readings recorded this

  • plasma folic acid and methylcobalamin levels

    decreases, p = 0.05

    After 12-week treatment the plasma folic acid and methylcobalamin, and Hcy levels decreased and serum HTase/PON activity increased significantly in the three groups receiving intervention treatment (all P < 0.05)

    PMID 17425871 · one of two readings recorded this

  • plasma total homocysteine, percentage decrease

    decreases, p = 0.01

    The Hcy level decreased by 2.8% in Group I, 14.0% in Group II, 37.3% in Group III, and 21.7% in Group IV respectively (all P < 0.01)

    PMID 17425871 · one of two readings recorded this

  • serum HTase/PON activity, percentage increase

    increases, p = 0.05

    The HTase/PON activity increased by 2.7% in Group I, 8.0% in Group II, 3.4% in Group III, and 17.6% in Group IV respectively (all P < 0.05)

    PMID 17425871 · one of two readings recorded this

  • fasting blood glucose (FBG)

    modulates, p = 0.01

    FBG, GHB, hemorheological indexes, plasma ET, NO and MDA significantly improved in the mild-warm moxibustion group (P < 0.01)

    PMID 18257180 · one of two readings recorded this

  • FBG, GHB, hemorheological indexes, ET, NO and MDA, moxibustion versus acupuncture

    no effect, p = 0.05

    with no significant difference as compared with those in the acupuncture group (P > 0.05)

    PMID 18257180 · one of two readings recorded this

  • FBG, GHB, hemorheological indexes, ET, NO and MDA, moxibustion versus medication

    modulates, p = 0.05

    but with a significant difference as compared with the medication group (P < 0.05)

    PMID 18257180 · one of two readings recorded this

  • glycosylated hemoglobin (GHB)

    modulates, p = 0.01

    FBG, GHB, hemorheological indexes, plasma ET, NO and MDA significantly improved in the mild-warm moxibustion group (P < 0.01)

    PMID 18257180 · one of two readings recorded this

  • hemorheological indexes

    modulates, p = 0.01

    FBG, GHB, hemorheological indexes, plasma ET, NO and MDA significantly improved in the mild-warm moxibustion group (P < 0.01)

    PMID 18257180 · one of two readings recorded this

  • plasma endothelin (ET)

    modulates, p = 0.01

    FBG, GHB, hemorheological indexes, plasma ET, NO and MDA significantly improved in the mild-warm moxibustion group (P < 0.01)

    PMID 18257180 · one of two readings recorded this

  • plasma malondialdehyde (MDA)

    modulates, p = 0.01

    FBG, GHB, hemorheological indexes, plasma ET, NO and MDA significantly improved in the mild-warm moxibustion group (P < 0.01)

    PMID 18257180 · one of two readings recorded this

  • plasma nitric oxide (NO)

    modulates, p = 0.01

    FBG, GHB, hemorheological indexes, plasma ET, NO and MDA significantly improved in the mild-warm moxibustion group (P < 0.01)

    PMID 18257180 · one of two readings recorded this

  • total effective rate

    The total effective rate was 90.0%

    PMID 18257180 · one of two readings recorded this

  • correlation between changes in HTase/PON activity and Hcy

    decreases, p = 0.004

    There was a significant inverse correlation between the changes in HTase/PON activity and Hcy levels (r=-0.29, P=0.004)

    PMID 18781288 · one of two readings recorded this

  • plasma homocysteine after vitamin supplementation

    decreases

    After vitamin supplementation there was a significant reduction in plasma Hcy levels

    PMID 18781288 · one of two readings recorded this

  • plasma homocysteine, diabetics versus controls

    decreases, p = 0.05

    Serum HTase/PON activity was significantly higher in diabetics compared with controls, plasma Hcy levels were significantly lower (P<0.05)

    PMID 18781288 · one of two readings recorded this

  • plasma homocysteine, mean percentage reduction

    decreases

    The mean percentage reduction in Hcy was 2.75% in group I, 14% in group II and 37.3% in group III

    PMID 18781288 · one of two readings recorded this

  • serum HTase/PON activity, diabetics versus controls

    increases, p = 0.05

    Serum HTase/PON activity was significantly higher in diabetics compared with controls, plasma Hcy levels were significantly lower (P<0.05)

    PMID 18781288 · one of two readings recorded this

  • serum HTase/PON activity, percentage increase

    increases, p = 0.001

    A 2.72% increase in HTase/PON activity was seen in group I, an 8.03% increase was detected when folic acid was given in group II (P<0.001), and a 17.59% increase in HTase/PON activity was seen in group III (P<0.001)

    PMID 18781288 · one of two readings recorded this

  • control rate

    the control rate half a year after the treatment was 45.7%, 27.8%, 36.0%, respectively

    PMID 19160857 · one of two readings recorded this

  • effective rate and control rate, intratympanic perfusion versus carbamazepine

    no effect

    There was no statistically significant difference in the effective rate and control rate between intratympanic perfusion group and carbamazepine group

    PMID 19160857 · one of two readings recorded this

  • effective rate and control rate, prednisolone versus dexamethasone

    modulates

    There is a statistically significant difference both in the effective rate and the control rate between the prednisolone group and the dexamethasone group

    PMID 19160857 · one of two readings recorded this

  • effective rate

    The effective rate of the prednisolone group, dexamethasone group and the carbamazepine group was 48.6%, 33.3%, 44.0%, respectively

    PMID 19160857 · one of two readings recorded this

  • urinary bother, UCLA-PCI

    no effect, p = 0.168, n = 54

    group A tended to have a better URF than group B (85.7 +/- 4.7 (mean +/- standard error) vs. 66.9 +/- 10.2) and URB (85.7 +/- 7.4 vs. 63.9 +/- 11.8) (p = 0.121, p = 0.168)

    PMID 19198223 · one of two readings recorded this

  • urinary function, UCLA-PCI

    no effect, p = 0.121, n = 54

    group A tended to have a better URF than group B (85.7 +/- 4.7 (mean +/- standard error) vs. 66.9 +/- 10.2) and URB (85.7 +/- 7.4 vs. 63.9 +/- 11.8) (p = 0.121, p = 0.168)

    PMID 19198223 · one of two readings recorded this

  • urinary function, urinary bother, sexual function and sexual bother on the UCLA Prostate Cancer Index after nerve sparing radical prostatectomy

    no effect

    Not recorded as a finding: this platform holds no node for the endpoint

    There were no significant differences in URF, URB, SXF or SXB between the two groups at any postoperative period.

    PMID 19198223 · both readings recorded this

  • urinary function, urinary bother, sexual function and sexual bother, UCLA-PCI

    no effect

    There were no significant differences in URF, URB, SXF or SXB between the two groups at any postoperative period

    PMID 19198223 · one of two readings recorded this

  • LF

    decreases

    low frequency (LF, ms2) 379.90 +/- 159.07 vs 477.70 +/- 396.91

    PMID 19213352 · one of two readings recorded this

  • clinical efficacy grade, clinically cured

    while the corresponding data in the control group were 2 (8%), 4 (16%), 18 (72%) and 1 (4%) respectively

    PMID 19213352 · one of two readings recorded this

  • clinical efficacy grade, clinically cured

    5 patients (20%) were clinically cured

    PMID 19213352 · one of two readings recorded this

  • clinical efficacy, treatment versus control

    increases, p = 0.05, n = 50

    demonstrating the efficacy in the treatment group was superior to that in the control group (P <0.05)

    PMID 19213352 · one of two readings recorded this

  • HF

    increases

    high frequency (HF, ms2) 157.10 +/- 28.18 vs 122.10 +/- 101.90

    PMID 19213352 · one of two readings recorded this

  • HRV indexes, all

    modulates, p = 0.05

    All were superior in the treatment group (P < 0.05)

    PMID 19213352 · one of two readings recorded this

  • HRV indexes before treatment

    no effect, p = 0.05

    Before treatment, the HRV indexes in the two groups were insignificantly different respectively (P >0.05)

    PMID 19213352 · one of two readings recorded this

  • HRVTI

    increases

    HRV trigonometric index (HRVTI) 35.10 +/- 4.48 vs 25.51 +/- 2.24

    PMID 19213352 · one of two readings recorded this

  • LF/HF ratio

    decreases

    LF/HF ratio 2.37 +/- 0.52 vs 4.27 +/- 2.84

    PMID 19213352 · one of two readings recorded this

  • SDANN

    increases

    average standard deviation of 5 min NN intervals (SDANN, ms) 126.90 +/- 9.99 vs 106.20 +/- 8.84

    PMID 19213352 · one of two readings recorded this

  • SDNN

    increases

    standard deviation of NN intervals (SDNN, ms) 133.41 +/- 8.61 vs 115.61 +/- 13.49

    PMID 19213352 · one of two readings recorded this

  • augmentation index in the carotid artery

    decreases, p = 0.03

    Not recorded as a finding: the sentence reports a change in only the methylcobalamin group, not a stated between-arm contrast (within_arm_only)

    Augmentation index was decreased in only the methylcobalamin group (P = 0.03).

    PMID 20430500 · both readings recorded this

  • augmentation index in the carotid artery

    decreases, p = 0.03, n = 20

    Augmentation index was decreased in only the methylcobalamin group (P = 0.03)

    PMID 20430500 · one of two readings recorded this

  • normalization of plasma homocysteine (<15 umol/L)

    increases, 18 of 20 vs 6 of 20 normalized, n = 40

    Not recorded as a finding: no outcome node for plasma homocysteine

    The proportion showing normalization of plasma homocysteine levels was much greater in the methylcobalamin group (18 of 20 patients; 90%) than in the folate group (6 of 20; 30%; P < 0.001).

    PMID 20430500 · one of two readings recorded this

  • percentage decrease in serum ADMA

    decreases, p = 0.001, n = 40

    The percentage of decrease in ADMA levels was greater in the methylcobalamin than folate group (25.4% +/- 10.2% vs 13.2% +/- 11.2%; P < 0.001)

    PMID 20430500 · one of two readings recorded this

  • plasma homocysteine normalization (<15 umol/L), proportion

    increases, 18 of 20 (90%) vs 6 of 20 (30%)

    Not recorded as a finding: No outcome node for homocysteine

    The proportion showing normalization of plasma homocysteine levels was much greater in the methylcobalamin group (18 of 20 patients; 90%) than in the folate group (6 of 20; 30%; P < 0.001).

    PMID 20430500 · one of two readings recorded this

  • proportion with normalization of plasma homocysteine (<15 mumol/L)

    increases, p = 0.001, n = 40

    The proportion showing normalization of plasma homocysteine levels was much greater in the methylcobalamin group (18 of 20 patients; 90%) than in the folate group (6 of 20; 30%; P < 0.001)

    PMID 20430500 · one of two readings recorded this

  • ratio of dimethylamine to ADMA

    increases, p = 0.04, n = 20

    however, the ratio of dimethylamine to ADMA was increased in only the methylcobalamin group (P = 0.04)

    PMID 20430500 · one of two readings recorded this

  • ratio of S-adenosylmethionine to S-adenosylhomocysteine

    no effect, n = 40

    The increase in ratio of S-adenosylmethionine to S-adenosylhomocysteine was not different between the 2 groups

    PMID 20430500 · one of two readings recorded this

  • 1-point (tactile) static testing of cutaneous sensitivity at the right and left great toe and heel

    increases, n = 20

    Statistically significant improvement in 1-point (tactile) and 2-point (discriminatory) static testing at the right and left great toe and heel in the patients was observed in all 3 follow-up periods

    PMID 21206429 · one of two readings recorded this

  • 2-point (discriminatory) static testing of cutaneous sensitivity at the right and left great toe and heel

    increases, n = 20

    Statistically significant improvement in 1-point (tactile) and 2-point (discriminatory) static testing at the right and left great toe and heel in the patients was observed in all 3 follow-up periods

    PMID 21206429 · one of two readings recorded this

  • cutaneous sensitivity improvement, largest between follow-up periods

    increases, n = 20

    The greatest improvement occurred between baseline and 1 year of treatment

    PMID 21206429 · one of two readings recorded this

  • fasting plasma total homocysteine

    decreases

    The supplement group had average plasma tHCY reduced to 9.3 ± 2.7 μmol/L

    PMID 21216507 · one of two readings recorded this

  • Mattis dementia rating scale, global cognitive decline

    no effect

    Homocysteine lowering in dementia patients did not significantly reduce global cognitive decline

    PMID 21216507 · one of two readings recorded this

  • MDRS construction domain decline

    decreases, p = 0.003

    the decline in MDRS (construction domain) was significantly smaller in the supplement group (median 0 versus 2 points in placebo group, P = 0.003)

    PMID 21216507 · one of two readings recorded this

  • neuropsychological scores, change

    no effect

    There was no significant group difference in changes in any of the neuropsychological scores

    PMID 21216507 · one of two readings recorded this

  • effective rate

    increases, p = 0.05, n = 60

    The effective rates were 90.0% (27/30) and 63.3% (19/30) in group A and group B respectively, presenting significant statistical difference (P < 0.05)

    PMID 21823284 · one of two readings recorded this

  • motor and sensory nerve conduction velocity of ulnar and tibial nerve

    increases, p = 0.05

    the motor nerve conduction velocity (MCV) and sensory nerve conduction velocity (SCV) of ulnar nerve and tibial nerve in group A were higher than those in group B (P < 0.05, P < 0.01)

    PMID 21823284 · one of two readings recorded this

  • score of Chinese medicine syndrome

    decreases, p = 0.01

    the score of Chinese medicine syndrome in group A was lower than that in group B (14.36 +/- 1.88 vs 26.58 +/- 3.52, P < 0.01)

    PMID 21823284 · one of two readings recorded this

  • score of diabetic peripheral neuropathy

    decreases, p = 0.01

    the score of diabetic peripheral neuropathy in group A was lower than that in group B (12.86 +/- 4.28 vs 17.89 +/- 4.35, P < 0.01)

    PMID 21823284 · one of two readings recorded this

  • Oswestry Disability Index questionnaire Version 2.0, disability score

    decreases

    Not recorded as a finding: No outcome node for the Oswestry Disability Index

    There was a significant improvement in the Oswestry Disability Index and Visual Analogue Scale pain scores in the methylcobalamin group as compared with the placebo group (p-value less than 0.05).

    PMID 22159928 · one of two readings recorded this

  • Oswestry Disability Index questionnaire version 2.0 score

    decreases

    Not recorded as a finding: no outcome node for the Oswestry Disability Index

    There was a significant improvement in the Oswestry Disability Index and Visual Analogue Scale pain scores in the methylcobalamin group as compared with the placebo group (p-value less than 0.05).

    PMID 22159928 · one of two readings recorded this

  • Oswestry Disability Index

    decreases, p = 0.05, n = 58

    There was a significant improvement in the Oswestry Disability Index and Visual Analogue Scale pain scores in the methylcobalamin group as compared with the placebo group (p-value less than 0.05)

    PMID 22159928 · one of two readings recorded this

  • Visual Analogue Scale pain score

    decreases, p = 0.05, n = 58

    There was a significant improvement in the Oswestry Disability Index and Visual Analogue Scale pain scores in the methylcobalamin group as compared with the placebo group (p-value less than 0.05)

    PMID 22159928 · one of two readings recorded this

  • Total effective rate (recovery of lower limb sensation disorder)

    increases, p = 0.05

    The total effective rate was 90.0% (36/40) in plum-blossom needle group, superior to that of 60.0% (24/40) in western medication group (P < 0.05)

    PMID 22493916 · one of two readings recorded this

  • Total effective rate (recovery of lower limb sensation disorder)

    The total effective rate was 90.0% (36/40) in plum-blossom needle group, superior to that of 60.0% (24/40) in western medication group (P < 0.05)

    PMID 22493916 · one of two readings recorded this

  • Total effective rate (recovery of lower limb sensation disorder)

    no effect, p = 0.05

    there was no significant differences between the cases which received the treatment during 1-3 months after operation and more than 3 months after operation (P > 0.05)

    PMID 22493916 · one of two readings recorded this

  • Total effective rate (recovery of lower limb sensation disorder)

    increases, p = 0.05

    the effect for the cases which received treatment within one month after operation was superior to that received treatment during 1-3 months after operation (P < 0.05)

    PMID 22493916 · one of two readings recorded this

  • total effectiveness rate and clinical cure rate, acupuncture versus other treatments including carbamazepine, mecobalamin and massage

    increases

    All studies reported that acupuncture was superior to other treatments, including carbamazepine, mecobalamin, and massage, and the meta-analysis on these low-quality studies yielded similar results

    PMID 22875561 · one of two readings recorded this

  • Total effective rate (hearing improvement)

    The total effective rate was 89.2% (66/74) in the warming-promoting needling group, which was better than 62.5% (35/56) in the conventional acupuncture group and 53.4% (31/58) in the medication group (both P<0.01)

    PMID 23213981 · one of two readings recorded this

  • Total effective rate (hearing improvement)

    The total effective rate was 89.2% (66/74) in the warming-promoting needling group, which was better than 62.5% (35/56) in the conventional acupuncture group and 53.4% (31/58) in the medication group (both P<0.01)

    PMID 23213981 · one of two readings recorded this

  • Total effective rate (hearing improvement)

    increases, p = 0.01

    The total effective rate was 89.2% (66/74) in the warming-promoting needling group, which was better than 62.5% (35/56) in the conventional acupuncture group and 53.4% (31/58) in the medication group (both P<0.01)

    PMID 23213981 · one of two readings recorded this

  • Neuropathy Total Symptom Score (NTSS-6) at weeks 16 and 24 in type 2 diabetes with neuropathy; vibration perception threshold was the primary endpoint

    clinically significant improvement in NTSS-6 scores at week 16 (P=.013 vs placebo) and week 24 (P=.033), p = 0.033

    Not recorded as a finding: the intervention held more than the compound

    However, patients receiving LMF-MC-PLP consistently reported symptomatic relief, with clinically significant improvement in NTSS-6 scores at week 16 (P=.013 vs placebo) and week 24 (P=.033).

    PMID 23218892 · one of two readings recorded this

  • Neuropathy Total Symptom Score (NTSS-6)

    decreases, p = 0.013

    clinically significant improvement in NTSS-6 scores at week 16 (P=.013 vs placebo) and week 24 (P=.033)

    PMID 23218892 · one of two readings recorded this

  • Neuropathy Total Symptom Score (NTSS-6)

    decreases, p = 0.033

    clinically significant improvement in NTSS-6 scores at week 16 (P=.013 vs placebo) and week 24 (P=.033)

    PMID 23218892 · one of two readings recorded this

  • Plasma homocysteine

    decreases, p = 0.0001

    Homocysteine decreased by 2.7±3.0 μmol/L with LMF-MC-PLP versus an increase of 0.5±2.4 μmol/L with placebo (P=.0001)

    PMID 23218892 · one of two readings recorded this

  • Quality-of-life measures (SF-36)

    increases

    Quality-of-life measures also improved

    PMID 23218892 · one of two readings recorded this

  • Vibration perception threshold (VPT)

    no effect

    There was no significant effect on VPT

    PMID 23218892 · one of two readings recorded this

  • Mean numerical pain scale (NPS)

    no effect

    NPS scores were statistically similar by the end of 90 days

    PMID 23279193 · one of two readings recorded this

  • Mean numerical pain scale (NPS)

    decreases

    Over the follow-up of 90 days, the mean NPS in group A decreased from 6 ± 2 to 3 ± 2 and in group B from 5 ± 1 to 2 ± 2

    PMID 23279193 · one of two readings recorded this

  • Mean numerical pain scale (NPS)

    decreases

    Over the follow-up of 90 days, the mean NPS in group A decreased from 6 ± 2 to 3 ± 2 and in group B from 5 ± 1 to 2 ± 2

    PMID 23279193 · one of two readings recorded this

  • Time to improvement in BPI emotion interference

    decreases

    Improvement from baseline in BPI measurement of QOL (mood, interpersonal relationship, and emotion) was earlier in group B (1, 2, and 1 months, respectively) compared with group A (2, 3, and 2 months, respectively)

    PMID 23279193 · one of two readings recorded this

  • Time to improvement in BPI emotion interference

    decreases

    Improvement from baseline in BPI measurement of QOL (mood, interpersonal relationship, and emotion) was earlier in group B (1, 2, and 1 months, respectively) compared with group A (2, 3, and 2 months, respectively)

    PMID 23279193 · one of two readings recorded this

  • Time to improvement in BPI interpersonal relationship interference

    decreases

    Improvement from baseline in BPI measurement of QOL (mood, interpersonal relationship, and emotion) was earlier in group B (1, 2, and 1 months, respectively) compared with group A (2, 3, and 2 months, respectively)

    PMID 23279193 · one of two readings recorded this

  • Time to improvement in BPI interpersonal relationship interference

    decreases

    Improvement from baseline in BPI measurement of QOL (mood, interpersonal relationship, and emotion) was earlier in group B (1, 2, and 1 months, respectively) compared with group A (2, 3, and 2 months, respectively)

    PMID 23279193 · one of two readings recorded this

  • Time to improvement in BPI mood interference

    decreases

    Improvement from baseline in BPI measurement of QOL (mood, interpersonal relationship, and emotion) was earlier in group B (1, 2, and 1 months, respectively) compared with group A (2, 3, and 2 months, respectively)

    PMID 23279193 · one of two readings recorded this

  • Time to improvement in BPI mood interference

    decreases

    Improvement from baseline in BPI measurement of QOL (mood, interpersonal relationship, and emotion) was earlier in group B (1, 2, and 1 months, respectively) compared with group A (2, 3, and 2 months, respectively)

    PMID 23279193 · one of two readings recorded this

  • Lequesne Index score

    decreases, p = 0.05

    Lequesne Index score, -0.60±0.06 versus -0.84±0.09, P=0.05

    PMID 23354008 · one of two readings recorded this

  • Net change in AGEs

    decreases, p = 0.001

    AGEs, -0.12±0.02 versus -0.99±0.09, arbitrary florescence units, P=0.001

    PMID 23354008 · one of two readings recorded this

  • Net change in C-reactive protein

    decreases, p = 0.01

    C-reactive protein, -0.12±0.35 versus -2.45±0.60 mg/L, P<0.01

    PMID 23354008 · one of two readings recorded this

  • Net change in serum nitrite

    decreases, p = 0.001

    Net change in serum nitrite, -0.15±0.01 versus -0.79±0.12 µmol/L, P<0.001

    PMID 23354008 · one of two readings recorded this

  • Net change in thiobarbituric acid reactive substances

    decreases, p = 0.01

    thiobarbituric acid reactive substances, -0.69±0.12 versus -1.80±0.12 nmol/L, P<0.01

    PMID 23354008 · one of two readings recorded this

  • Net decrease in pain score

    decreases, p = 0.003

    At 24 weeks, net decrease in pain score, -6.64±2.71 versus -8.20±1.28, P=0.003

    PMID 23354008 · one of two readings recorded this

  • Time taken for 20-m walk test

    no effect, p = 1

    time taken for 20-m walk test, -5.0±1.39 versus -5.0±0.92 s, P=1.00

    PMID 23354008 · one of two readings recorded this

  • Total WOMAC score

    decreases, p = 0.013

    total WOMAC score, -5.88±0.84 versus -8.26±1.24, P=0.013

    PMID 23354008 · one of two readings recorded this

  • activities of daily living and quality of life

    increases, p = 0.001

    Twenty subjects achieved pain reduction ≥ 50%, 24 perceived worst pain ≤ 3, 24 stopped using analgesics at end point; activities of daily living and quality of life improved significantly as compared with the other groups (P < 0.001)

    PMID 23566267 · one of two readings recorded this

  • allodynia

    decreases, p = 0.05

    In the injected methylcobalamin group, the overall pain (P < 0.001), continuous spontaneous pain (P < 0.05), paroxysmal pain (P < 0.05), and allodynia (P < 0.05) revealed a significant effect at each follow-up point as compared with the other groups

    PMID 23566267 · one of two readings recorded this

  • continuous spontaneous pain

    decreases, p = 0.05

    In the injected methylcobalamin group, the overall pain (P < 0.001), continuous spontaneous pain (P < 0.05), paroxysmal pain (P < 0.05), and allodynia (P < 0.05) revealed a significant effect at each follow-up point as compared with the other groups

    PMID 23566267 · one of two readings recorded this

  • overall pain, time per group interaction and group difference

    modulates, p = 0.001

    Time per group interaction and group difference on overall pain at each follow-up point were statistically significant (P < 0.001) among groups

    PMID 23566267 · one of two readings recorded this

  • overall pain

    decreases, p = 0.001

    In the injected methylcobalamin group, the overall pain (P < 0.001), continuous spontaneous pain (P < 0.05), paroxysmal pain (P < 0.05), and allodynia (P < 0.05) revealed a significant effect at each follow-up point as compared with the other groups

    PMID 23566267 · one of two readings recorded this

  • pain relief

    no effect, p = 0.05

    Although both of the other groups showed a significant response after the 14-day treatment (P < 0.001) compared with the baseline, oral methylcobalamin did not provide any significantly pain relief (P > 0.05)

    PMID 23566267 · one of two readings recorded this

  • pain response versus baseline after 14-day treatment

    decreases, p = 0.001

    Although both of the other groups showed a significant response after the 14-day treatment (P < 0.001) compared with the baseline, oral methylcobalamin did not provide any significantly pain relief (P > 0.05)

    PMID 23566267 · one of two readings recorded this

  • paroxysmal pain

    decreases, p = 0.05

    In the injected methylcobalamin group, the overall pain (P < 0.001), continuous spontaneous pain (P < 0.05), paroxysmal pain (P < 0.05), and allodynia (P < 0.05) revealed a significant effect at each follow-up point as compared with the other groups

    PMID 23566267 · one of two readings recorded this

  • subjects achieving pain reduction of 50% or more

    increases

    Twenty subjects achieved pain reduction ≥ 50%, 24 perceived worst pain ≤ 3, 24 stopped using analgesics at end point; activities of daily living and quality of life improved significantly as compared with the other groups (P < 0.001)

    PMID 23566267 · one of two readings recorded this

  • subjects who stopped using analgesics

    decreases

    Twenty subjects achieved pain reduction ≥ 50%, 24 perceived worst pain ≤ 3, 24 stopped using analgesics at end point; activities of daily living and quality of life improved significantly as compared with the other groups (P < 0.001)

    PMID 23566267 · one of two readings recorded this

  • subjects with worst pain 3 or less

    decreases

    Twenty subjects achieved pain reduction ≥ 50%, 24 perceived worst pain ≤ 3, 24 stopped using analgesics at end point; activities of daily living and quality of life improved significantly as compared with the other groups (P < 0.001)

    PMID 23566267 · one of two readings recorded this

  • effectiveness

    decreases

    There was low and very low-quality evidence from six trials that multimodal nonoperative treatment is less effective than indirect or direct surgical decompression with or without fusion

    PMID 23996271 · one of two readings recorded this

  • function

    no effect

    no significant difference in function at six months (mean difference (MD) -3.66, 95% CI -10.12 to 2.80)

    PMID 23996271 · one of two readings recorded this

  • function

    unclear

    at 24 months a significant difference was found favouring decompression (MD -4.43, 95% CI -7.91 to -0.96)

    PMID 23996271 · one of two readings recorded this

  • leg pain and function

    increases

    There was low-quality evidence from a single trial that exercise is of short-term benefit for leg pain and function compared with no treatment

    PMID 23996271 · one of two readings recorded this

  • pain and other outcomes assessed

    no effect

    There was very low-quality evidence from six trials that calcitonin is no better than placebo or paracetamol, regardless of mode of administration or outcome assessed

    PMID 23996271 · one of two readings recorded this

  • pain, function, and quality of life

    increases

    epidural steroid injections improved pain, function, and quality of life, up to two weeks, compared with home exercise or inpatient physical therapy

    PMID 23996271 · one of two readings recorded this

  • walking distance

    increases

    very low-quality evidence for gabapentin or methylcobalamin that they improved walking distance

    PMID 23996271 · one of two readings recorded this

  • walking distance

    increases

    very low-quality evidence for gabapentin or methylcobalamin that they improved walking distance

    PMID 23996271 · one of two readings recorded this

  • walking distance

    increases

    From single small trials, there was low-quality evidence for prostaglandins, and very low-quality evidence for gabapentin or methylcobalamin that they improved walking distance

    PMID 23996271 · one of two readings recorded this

  • DEB-NTC grade 1 neuropathy

    In the GJG group, grade 1 DEB-NTC was observed in 2 cases, grade 2 in 5 cases and grade 3 in 5 cases

    PMID 24377531 · one of two readings recorded this

  • DEB-NTC grade 2 neuropathy

    In the B12 group, grades 1, 2 and 3 DEB-NTC were observed in one case, 12 cases and 12 cases, respectively

    PMID 24377531 · one of two readings recorded this

  • DEB-NTC grade 2 neuropathy

    In the GJG group, grade 1 DEB-NTC was observed in 2 cases, grade 2 in 5 cases and grade 3 in 5 cases

    PMID 24377531 · one of two readings recorded this

  • DEB-NTC grade 3 neuropathy

    In the B12 group, grades 1, 2 and 3 DEB-NTC were observed in one case, 12 cases and 12 cases, respectively

    PMID 24377531 · one of two readings recorded this

  • DEB-NTC grade 3 neuropathy

    In the GJG group, grade 1 DEB-NTC was observed in 2 cases, grade 2 in 5 cases and grade 3 in 5 cases

    PMID 24377531 · one of two readings recorded this

  • Incidence of neuropathy

    p = 0.01

    The incidence of neuropathy was 39.3% in the GJG group, and 88.9% in the B12 group (p<0.01)

    PMID 24377531 · one of two readings recorded this

  • Incidence of neuropathy

    decreases, p = 0.01

    The incidence of neuropathy was 39.3% in the GJG group, and 88.9% in the B12 group (p<0.01)

    PMID 24377531 · one of two readings recorded this

  • NCI-CTC grade 1 neuropathy

    grades 1, 2 and 3 NCI-CTC were observed in 11 cases, 12 cases and one case

    PMID 24377531 · one of two readings recorded this

  • NCI-CTC grade 1 neuropathy

    Grade 1 NCI-CTC was observed in 7 cases, grade 2 in 6 cases

    PMID 24377531 · one of two readings recorded this

  • NCI-CTC grade 2 neuropathy

    grades 1, 2 and 3 NCI-CTC were observed in 11 cases, 12 cases and one case

    PMID 24377531 · one of two readings recorded this

  • NCI-CTC grade 2 neuropathy

    Grade 1 NCI-CTC was observed in 7 cases, grade 2 in 6 cases

    PMID 24377531 · one of two readings recorded this

  • VAS

    VAS was 4.9 ± 2.4

    PMID 24377531 · one of two readings recorded this

  • VAS

    VAS was 2.7 ± 2.2

    PMID 24377531 · one of two readings recorded this

  • efficacy

    increases

    PGE1-MC combination therapy was significantly better than MC monotherapy (RR = 1.40; 95 % CI 1.33-1.48) on efficacy

    PMID 24522613 · one of two readings recorded this

  • median motor nerve conduction velocity

    increases

    6.72 (95 % CI: 5.42-8.02) for median motor nerve conduction velocity (MNCV)

    PMID 24522613 · one of two readings recorded this

  • median sensory nerve conduction velocity

    increases

    5.13 (CI 4.13-6.13) for median sensory nerve conduction velocity (SNCV)

    PMID 24522613 · one of two readings recorded this

  • peroneal motor nerve conduction velocity

    increases

    5.74 (CI 4.87-6.61) for peroneal MNCV

    PMID 24522613 · one of two readings recorded this

  • peroneal sensory nerve conduction velocity

    increases

    4.62 (CI 3.89-5.34) for peroneal SNCV

    PMID 24522613 · one of two readings recorded this

  • efficiency by age

    increases

    Regard of age, the efficiency of NGF treatment group was significantly higher than control group

    PMID 25129979 · one of two readings recorded this

  • efficiency, high pre-treatment PTA

    no effect

    For the patients whose duration were more than 7 d, or the PTA>60 dBHL, the efficiency of NGF therapy was not superior to the traditional treatment

    PMID 25129979 · one of two readings recorded this

  • efficiency, long duration

    no effect

    For the patients whose duration were more than 7 d, or the PTA>60 dBHL, the efficiency of NGF therapy was not superior to the traditional treatment

    PMID 25129979 · one of two readings recorded this

  • efficiency, low pre-treatment PTA

    increases

    For the patients whose duration were less than 7 d, or the PTA < or = 60 dBHL, the efficiency of NGF group were significantly higher

    PMID 25129979 · one of two readings recorded this

  • efficiency, short duration

    increases

    For the patients whose duration were less than 7 d, or the PTA < or = 60 dBHL, the efficiency of NGF group were significantly higher

    PMID 25129979 · one of two readings recorded this

  • total efficiency

    increases, n = 115

    The total efficiency of NGF group was significantly higher than control group

    PMID 25129979 · one of two readings recorded this

  • JOA score

    unclear, p = 0.05

    The JOA score at 6 months of followed-ups was superior in the treatment group to that of the control group (P < 0.05)

    PMID 25137843 · one of two readings recorded this

  • JOA score

    unclear

    The JOA scores were improved after treatment, at 6 and 12 months of followed-ups (P < 0.05, P < 0.01)

    PMID 25137843 · one of two readings recorded this

  • occurrence of failed back surgery syndrome, group comparison

    decreases, p = 0.05

    The treatment group was superior to the control group (P < 0.05)

    PMID 25137843 · one of two readings recorded this

  • occurrence of failed back surgery syndrome

    decreases

    Five patients (accounting for 10.6%) suffered from FBSS in the treatment group, while 9 (accounting for 19.6%) suffered from FBSS in the control group

    PMID 25137843 · one of two readings recorded this

  • patients completing follow-up

    n = 93

    Totally 93 patients completed the followed-up study

    PMID 25137843 · one of two readings recorded this

  • serum TNF-alpha level, group comparison

    unclear, p = 0.05

    the improvement of TNF-alpha in the treatment group was better than that of the control group (P < 0.05)

    PMID 25137843 · one of two readings recorded this

  • serum TNF-alpha level

    unclear

    The TNFalpha level was improved after treatment in the two groups

    PMID 25137843 · one of two readings recorded this

  • Medical Research Council (MRC) sum score in at least two of 20 muscles, open-label single-arm, 1 year after intravenous methylcobalamin

    improved in seven of twelve evaluated patients, unchanged or worsened in five

    Not recorded as a finding: this platform holds no node for the endpoint

    Therefore, twelve patients were evaluated for the primary outcomes; the MRC sum score was improved in seven of the patients and unchanged or worsened in the remaining five patients.

    PMID 25175124 · one of two readings recorded this

  • MRC sum score improvement in at least two of 20 muscles

    increases

    Therefore, twelve patients were evaluated for the primary outcomes; the MRC sum score was improved in seven of the patients and unchanged or worsened in the remaining five patients

    PMID 25175124 · one of two readings recorded this

  • clinical symptoms and signs, cold water loading test and electroneuromyography

    increases, p = 0.05

    significant improvements in clinical symptoms and signs (hand numbness and pain, and reduced senses of touch, pain, and vibration), cold water loading test (CWLT), and electroneuromyography (ENMG) after treatments (P < 0.05)

    PMID 25608899 · one of two readings recorded this

  • clinical symptoms and signs, cold water loading test and electroneuromyography

    increases, p = 0.05

    significant improvements in clinical symptoms and signs (hand numbness and pain, and reduced senses of touch, pain, and vibration), cold water loading test (CWLT), and electroneuromyography (ENMG) after treatments (P < 0.05)

    PMID 25608899 · one of two readings recorded this

  • improvement, treatment group versus control group

    increases, p = 0.05

    And the treatment group had significantly more improvements than the control group (P < 0.05)

    PMID 25608899 · one of two readings recorded this

  • Median motor nerve conduction velocity (MNCV)

    increases, p = 0.0001

    The pooled WMD was 7.53, 95% CI was 4.65–10.42, Z was 5.11 (P < 0.0001)

    PMID 25866802 · one of two readings recorded this

  • Median sensory nerve conduction velocity (SNCV)

    increases, p = 0.003

    The pooled WMD was 4.98, 95% CI was 1.75–8.21, Z was 3.02 (P = 0.003)

    PMID 25866802 · one of two readings recorded this

  • Overall effectiveness (total efficiency)

    increases, p = 0.0001

    fixed effects model was employed for pooled analysis which showed that OR was 5.01, 95% CI was 3.70–6.78, Z was 10.44 (P < 0.0001)

    PMID 25866802 · one of two readings recorded this

  • Peroneal motor nerve conduction velocity (MNCV)

    increases, p = 0.0001

    The pooled OR was 6.20, 95% CI was 4.69–7.72, Z was 8.02 (P < 0.0001)

    PMID 25866802 · one of two readings recorded this

  • Peroneal sensory nerve conduction velocity (SNCV)

    increases, p = 0.0001

    The pooled OR was 4.06, 95% CI was 2.80–5.32, Z was 6.33 (P < 0.0001)

    PMID 25866802 · one of two readings recorded this

  • average pain duration before presenting to hospital

    Average pain duration before presenting to hospital is 260 min

    PMID 25923150 · one of two readings recorded this

  • complete pain relief

    no effect, p = 0.25

    84% of group A and 76% of group B had complete pain relief at the end of 3 hours (P = .25)

    PMID 25923150 · one of two readings recorded this

  • complete pain relief

    no effect, p = 0.75

    Sixteen percent in group A and 18% in group B had complete pain relief within 30 min (P = .75)

    PMID 25923150 · one of two readings recorded this

  • decrease in pain by each scoring method (VAS, verbal and facial response scales)

    no effect, p = 0.75

    Decrease in pain by each scoring method was also comparable (P = .75)

    PMID 25923150 · one of two readings recorded this

  • patients needing rescue drugs

    Fifteen patients in group A and 13 patients in group B needed rescue drugs

    PMID 25923150 · one of two readings recorded this

  • proportion of men in the study population

    81% of the study population were men

    PMID 25923150 · one of two readings recorded this

  • incidence of postherpetic neuralgia (PHN)

    The incidence of postherpetic neuralgia (PHN) was 2.04% at 3 months

    PMID 26200815 · one of two readings recorded this

  • mean pain score

    The mean pain scores in A1 (2.6 ± 0.7) and B1 (1.2 ± 0.8) decreased significantly compared with those in A0 (7.0 ± 1.7) and B0 (5.6 ± 1.9)

    PMID 26200815 · one of two readings recorded this

  • mean pain score

    decreases

    The mean pain scores in A1 (2.6 ± 0.7) and B1 (1.2 ± 0.8) decreased significantly compared with those in A0 (7.0 ± 1.7) and B0 (5.6 ± 1.9)

    PMID 26200815 · one of two readings recorded this

  • mean pain score

    The mean pain scores in A1 (2.6 ± 0.7) and B1 (1.2 ± 0.8) decreased significantly compared with those in A0 (7.0 ± 1.7) and B0 (5.6 ± 1.9)

    PMID 26200815 · one of two readings recorded this

The whole record — 1,487 rows